![]() ![]() While waiting for post-marketing clinical efficacy data (i.e., protection from symptomatic COVID19), many investigators have tested the neutralizing efficacy of monoclonal antibodies, convalescent plasma from previous waves or vaccinee sera in vitro to accelerate availability of surrogate endpoints. The majority of registration trials for currently approved monoclonal antibodies and vaccines were run either before the variants emerged, or enrolled patients in countries where such variants were not circulating at that time. ![]() Media-informed patients are questioning physicians about the relative efficacy of different vaccines and treatments against different variants. Nevertheless, emerging of SARS-CoV-2 variants of concern (VOC) and variants of interest (VOI) has diversified the landscape, jeopardizing the efforts to contain it. The ongoing SARS-CoV-2 pandemic has entered a new dimension thanks to availability of different vaccines and neutralizing antibody-based therapeutics (from convalescent plasma to monoclonal antibodies). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |